27 results on '"James, Stefan"'
Search Results
2. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
- Author
-
Capodanno, Davide, Mehran, Roxana, Krucoff, Mitchell W, Baber, Usman, Bhatt, Deepak L, Capranzano, Piera, Collet, Jean-Philippe, Cuisset, Thomas, De Luca, Giuseppe, De Luca, Leonardo, Farb, Andrew, Franchi, Francesco, Gibson, C Michael, Hahn, Joo-Yong, Hong, Myeong-Ki, James, Stefan, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A, Lopes, Renato D, Magee, Adrian, Matsumura, Ryosuke, Mochizuki, Shuichi, O'Donoghue, Michelle L, Pereira, Naveen L, Rao, Sunil V, Rollini, Fabiana, Shirai, Yuko, Sibbing, Dirk, Smits, Peter C, Steg, P Gabriel, Storey, Robert F, Ten Berg, Jurrien, Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, Serruys, Patrick W, Yeh, Robert W, Morice, Marie-Claude, and Angiolillo, Dominick J
- Subjects
610 Medicine & health - Abstract
Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or ischemic events in patients with coronary artery disease treated with percutaneous coronary intervention and those treated medically for an acute coronary syndrome. The use of antiplatelet therapy comes at the expense of an increased risk of bleeding complications. Defining the optimal intensity of platelet inhibition according to the clinical presentation of atherosclerotic cardiovascular disease and individual patient factors is a clinical challenge. Modulation of antiplatelet therapy is a medical action that is frequently performed to balance the risk of thrombotic or ischemic events and the risk of bleeding. This aim may be achieved by reducing (ie, de-escalation) or increasing (ie, escalation) the intensity of platelet inhibition by changing the type, dose, or number of antiplatelet drugs. Because de-escalation or escalation can be achieved in different ways, with a number of emerging approaches, confusion arises with terminologies that are often used interchangeably. To address this issue, this Academic Research Consortium collaboration provides an overview and definitions of different strategies of antiplatelet therapy modulation for patients with coronary artery disease, including but not limited to those undergoing percutaneous coronary intervention, and consensus statements on standardized definitions.
- Published
- 2023
- Full Text
- View/download PDF
3. Additional file 1 of A physically active lifestyle is associated with lower long-term incidence of bipolar disorder in a population-based, large-scale study
- Author
-
Svensson, Martina, Erhardt, Sophie, Hållmarker, Ulf, James, Stefan, and Deierborg, Tomas
- Abstract
Additional file 1: Figure S1. Flow diagram describing the Vasaloppet Study population. Table S1. Additional exclusion criteria. Table S2. Additional sensitivity analyses. Table S3. Additional sensitivity analyses stratified on sex.
- Published
- 2022
- Full Text
- View/download PDF
4. sj-pdf-1-ctj-10.1177_17407745211012438 – Supplemental material for Assessing the external validity of the VALIDATE-SWEDEHEART trial
- Author
-
Rylance, Rebecca T, Wagner, Philippe, Omerovic, Elmir, Held, Claes, James, Stefan, Koul, Sasha, and Erlinge, David
- Subjects
FOS: Clinical medicine ,160807 Sociological Methodology and Research Methods ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,FOS: Sociology - Abstract
Supplemental material, sj-pdf-1-ctj-10.1177_17407745211012438 for Assessing the external validity of the VALIDATE-SWEDEHEART trial by Rebecca T Rylance, Philippe Wagner, Elmir Omerovic, Claes Held, Stefan James, Sasha Koul and David Erlinge in Clinical Trials
- Published
- 2021
- Full Text
- View/download PDF
5. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
- Author
-
Ibanez, Borja, James, Stefan, Agewall, Stefan, Antunes, Manuel J., Bucciarelli-Ducci, Chiara, Bueno, Hector, Caforio, Alida L. P., Crea, Filippo, Goudevenos, John A., Halvorsen, Sigrun, Hindricks, Gerhard, Kastrati, Adnan, Lenzen, Mattie J., Prescott, Eva, Roffi, Marco, Valgimigli, Marco, Varenhorst, Christoph, Vranckx, Pascal, Widimský, Petr, Baumbach, Andreas, Bugiardini, Raffaele, Coman, Ioan Mircea, Delgado, Victoria, Fitzsimons, Donna, Gaemperli, Oliver, Gershlick, Anthony H., Gielen, Stephan, Harjola, Veli-Pekka, Katus, Hugo A., Knuuti, Juhani, Kolh, Philippe, Leclercq, Christophe, Lip, Gregory Y. H., Morais, Joao, Neskovic, Aleksandar N., Neumann, Franz-Josef, Niessner, Alexander, Piepoli, Massimo Francesco, Richter, Dimitrios J., Shlyakhto, Evgeny, Simpson, Iain A, Steg, Ph Gabriel, Terkelsen, Christian Juhl, Thygesen, Kristian, Windecker, Stephan, Zamorano, Jose Luis, Zeymer, Uwe, Ibanez, Borja, James, Stefan, Agewall, Stefan, Antunes, Manuel J., Bucciarelli-Ducci, Chiara, Bueno, Hector, Caforio, Alida L. P., Crea, Filippo, Goudevenos, John A., Halvorsen, Sigrun, Hindricks, Gerhard, Kastrati, Adnan, Lenzen, Mattie J., Prescott, Eva, Roffi, Marco, Valgimigli, Marco, Varenhorst, Christoph, Vranckx, Pascal, Widimskã½, Petr, Baumbach, Andrea, Bugiardini, Raffaele, Coman, Ioan Mircea, Delgado, Victoria, Fitzsimons, Donna, Gaemperli, Oliver, Gershlick, Anthony H., Gielen, Stephan, Harjola, Veli-Pekka, Katus, Hugo A., Knuuti, Juhani, Kolh, Philippe, Leclercq, Christophe, Lip, Gregory Y. H., Morais, Joao, Neskovic, Aleksandar N., Neumann, Franz-Josef, Niessner, Alexander, Piepoli, Massimo Francesco, Richter, Dimitrios J., Shlyakhto, Evgeny, Simpson, Iain A, Steg, Ph Gabriel, Terkelsen, Christian Juhl, Thygesen, Kristian, Windecker, Stephan, Zamorano, Jose Lui, and Zeymer, Uwe
- Subjects
Quality indicator ,medicine.medical_treatment ,Quality indicators ,Guideline ,ST-segment elevation ,030204 cardiovascular system & hematology ,0302 clinical medicine ,ST segment ,030212 general & internal medicine ,Myocardial infarction ,reproductive and urinary physiology ,Emergency medical system ,Evidence ,Risk assessment ,MINOCA ,Ischaemic heart disease ,Fibrinolysis ,Secondary prevention ,Primary percutaneous coronary intervention ,Reperfusion therapy ,Antithrombotics ,embryonic structures ,Cardiology ,Acute coronary syndrome ,biological phenomena, cell phenomena, and immunity ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Acute myocardial infarction ,Acute coronary syndromes ,Guidelines ,Antithrombotic therapy ,03 medical and health sciences ,Antithrombotic ,Internal medicine ,medicine ,Fibrinolysi ,In patient ,cardiovascular diseases ,urogenital system ,Task force ,business.industry ,medicine.disease ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,business - Abstract
The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
- Published
- 2017
6. Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease
- Author
-
Collet, Jean-Philippe, Roffi, Marco, Byrne, Robert A, Costa, Francesco, Valgimigli, Marco, Bueno, Héctor, Jeppsson, Anders, Jüni, Peter, Kastrati, Adnan, Kolh, Philippe, Mauri, Laura, Montalescot, Gilles, Neumann, Franz-Josef, Petricevic, Mate, Steg, Philippe Gabriel, Windecker, Stephan, Zamorano, Jose Luis, Badimon, Lina, Vranckx, Pascal, Agewall, Stefan, De Luca, Leonardo, Desmet, Walter, James, Stefan, Lettino, Maddalena, McFadden, Eugene Patrick, Storey, Robert, Ten Berg, Jurrien M, Aboyans, Victor, Jofresa, Alberto Berenguer, Biščević, Adela, Calabrò, Paolo, Constantinides, Savvas, Damrina, Elena, Diakite, Moustapha, Dzudovic, Boris, Ruiz, Victoria Garcia, Yáñez, Ivan Keituqwa, Lacalzada-Almeida, Juan, Leite, Luís, Maskon, Oteh, Myat, Lin Lin, Ricottini, Elisabetta, Saporito, Francesco, Wong, Peter Sze Chai, Yamaji, Kyohei, Zeitouni, Michel, Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC), ESC Scientific Document Group, Collet, Jean-Philippe, Roffi, Marco, Byrne, Robert A., Costa, Francesco, Valgimigli, Marco, Bueno, Hã©ctor, Jeppsson, Ander, Jã¼ni, Peter, Kastrati, Adnan, Kolh, Philippe, Mauri, Laura, Montalescot, Gille, Neumann, Franz-Josef, Petricevic, Mate, Steg, Philippe Gabriel, Windecker, Stephan, Zamorano, Jose Lui, Badimon, Lina, Vranckx, Pascal, Agewall, Stefan, De Luca, Leonardo, Desmet, Walter, James, Stefan, Lettino, Maddalena, Mcfadden, Eugene Patrick, Storey, Robert, Ten Berg, Jurrien M., Aboyans, Victor, Jofresa, Alberto Berenguer, BiÅ¡Ä ević, Adela, Calabro', Paolo, Constantinides, Savva, Damrina, Elena, Diakite, Moustapha, Dzudovic, Bori, Ruiz, Victoria Garcia, Yã¡ã±ez, Ivan Keituqwa, Lacalzada-Almeida, Juan, Leite, Luã, Maskon, Oteh, Myat, Lin Lin, Ricottini, Elisabetta, Saporito, Francesco, Wong, Peter Sze Chai, Yamaji, Kyohei, and Zeitouni, Michel
- Subjects
medicine.medical_specialty ,Aspirin ,business.industry ,MEDLINE ,dual antiplatelet therapy ,coronary artery disease ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,DUAL (cognitive architecture) ,medicine.disease ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Text mining ,Internal medicine ,Cardiology ,Medicine ,Humans ,Drug Therapy, Combination ,030212 general & internal medicine ,business ,Cardiology and Cardiovascular Medicine ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. Guidelines are presented throughout several case scenarios so the readership may better understand the research questions through case scenarios.
- Published
- 2017
7. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial
- Author
-
Franchi, Francesco, James, Stefan, Ghukasyan, Tatevik, Budaj, Andrzej J., Cornel, Jan H., Katus, Hugo A., Keltai, Matyas, Kontny, Frederic, Lewis, Basil S., Storey, Robert F., Himmelmann, Anders, Wallentin, Lars, Angiolillo, Dominick J., Parkhomenko, Alexander Nikolaevich, Oto, Ali, Skene, Allan, Budaj, Andrzej, Freij, Anneli, Santoso, Anwar, Armando, A, Meier, Bernhard, Yu, Cheuk Man, Cannon, Christopher P., Zambahari, Dato Seri Robaayah, Wu, Delon Wu, Ardissino, Diego, Raev, Dimitar, Kremastinos, Dimitrios, Weaver, Douglas, Paolasso, Ernesto, Giannitsis, Evangelos, Verheugt, Freek, Maurer, Gerald, Katus, Hugo, Emanuelsson, Hakan, Horrow, Jay, Bassand, Jean-Pierre, Spinar, Jindrich, Morais, Joao, Lopez Sendon, Jose, Nicolau, Jose, Seung, Ki-Bae, Teik, Lim Soo, Heras, Magda, Claeys, Marc J., Sabatine, Marc, Vintila, Marius, Ruda, Mikhail, Thorsen, Mona, Kleiman, Neil, Babilonia, Noe, Commerford, Patrick, Gurbel, Paul, Aylward, Phil, Steg, Philippe Gabriel, Theroux, Pierre, Sritara, Piyamitr, Pais, Prem, Becker, Richard, Lassila, Riitta, Harrington, Robert A., Gao, Runlin, Husted, Steen, Duris, Tibor, Chapichadze, Zaza, HUS Comprehensive Cancer Center, University Management, Department of Oncology, and PLATO Investigators
- Subjects
Male ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Comorbidity ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,FUNCTION PROFILES ,RESPONSIVENESS ,Electrocardiography ,0302 clinical medicine ,Risk Factors ,Coronary Heart Disease ,ARTERY-DISEASE ,Medicine ,Cardiac and Cardiovascular Systems ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Original Research ,Kardiologi ,Absolute risk reduction ,Diabetes, Type 2 ,DUAL ANTIPLATELET THERAPY ,Middle Aged ,Prognosis ,Clopidogrel ,female genital diseases and pregnancy complications ,3. Good health ,Survival Rate ,diabetes mellitus ,Female ,Cardiology and Cardiovascular Medicine ,Ticagrelor ,medicine.drug ,Platelets ,RENAL-FUNCTION ,medicine.medical_specialty ,Acute coronary syndrome ,ANTITHROMBOTIC THERAPY ,INHIBITION ,acute coronary syndrome ,ticagrelor ,03 medical and health sciences ,Internal medicine ,Diabetes mellitus ,Humans ,Renal Insufficiency, Chronic ,Aged ,Retrospective Studies ,Pharmacology ,clopidogrel ,Dose-Response Relationship, Drug ,business.industry ,Thrombosis ,medicine.disease ,United States ,REACTIVITY ,3121 General medicine, internal medicine and other clinical medicine ,Purinergic P2Y Receptor Antagonists ,Human medicine ,business ,Acute Coronary Syndromes ,Platelet Aggregation Inhibitors ,chronic kidney disease ,Follow-Up Studies ,Kidney disease - Abstract
Background There are limited data on how the combination of diabetes mellitus ( DM ) and chronic kidney disease ( CKD ) affects cardiovascular outcomes as well as response to different P2Y 12 receptor antagonists, which represented the aim of the present investigation. Methods and Results In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were classified into 4 groups: DM +/ CKD + (n=1058), DM +/ CKD − (n=2748), DM −/ CKD + (n=2160), and DM −/ CKD − (n=9142). The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary safety end point was PLATO major bleeding. DM +/ CKD + patients had a higher incidence of the primary end point compared with DM −/ CKD − patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88–2.63; P DM +/ CKD − and DM −/ CKD + had an intermediate risk profile. The same trend was shown for the individual components of the primary end point and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P ‐interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +. The effects on major bleeding were also consistent across subgroups ( P ‐interaction=0.288). Conclusions In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM and CKD , with patients having both risk factors at the highest risk. Although the ischemic benefit of ticagrelor over clopidogrel was consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD . Clinical Trial Registration URL : http://www.clinicatrials.gov . Unique identifier: NCT 00391872.
- Published
- 2019
8. Supplemental material for The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design
- Author
-
S Claiborne Johnston, Amarenco, Pierre, Denison, Hans, Evans, Scott R, Himmelmann, Anders, James, Stefan, Knutsson, Mikael, Ladenvall, Per, Molina, Carlos A, and Yongjun Wang
- Subjects
FOS: Clinical medicine ,Cardiology ,Medicine ,cardiovascular diseases ,110904 Neurology and Neuromuscular Diseases - Abstract
Supplemental Material for The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design by S Claiborne Johnston, Pierre Amarenco, Hans Denison, Scott R Evans, Anders Himmelmann, Stefan James, Mikael Knutsson, Per Ladenvall, Carlos A Molina, Yongjun Wang and for the THALES Investigators in International Journal of Stroke
- Published
- 2019
- Full Text
- View/download PDF
9. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
- Author
-
Bhatt, Deepak L., Fox, Kim, Harrington, Robert A., Leiter, Lawrence A., Mehta, Shamir R., Simon, Tabassome, Andersson, Marielle, Himmelmann, Anders, Ridderstrale, Wilhelm, Held, Claes, Steg, Philippe Gabriel, Steg, Gabriel, Diaz, Rafael, Amerena, John, Huber, Kurt, Sinnaeve, Peter, Nicolau, Jose Carlos, Kerr Saraiva, Jose Francisco, Petrov, Ivo, Corbalan, Ramon, Ge, Junbo, Zhao, Qiang, Botero, Rodrigo, Widimsky, Petr, Kristensen, Steen Dalby, Hartikainen, Juha, Danchin, Nicolas, Darius, Harald, Fat, Tse Hung, Kiss, Robert Gabor, Pais, Prem, Lev, Eli, De Luca, Leonardo, Goto, Shinya, Ramos Lopez, Gabriel Arturo, Cornel, Jan Hein, Kontny, Frederic, Medina, Felix, Babilonia, Noe, Opolski, Grzegorz, Vinereanu, Dragos, Zateyshchikov, Dmitry, Ruda, Mikhail, Elamin, Omer, Kovar, Frantisek, Dalby, Anthony John, Jeong, Myung Ho, Bueno, Hector, James, Stefan, Chiang, Chern-En, Tresukosol, Damras, Ongen, Zeki, Ray, Kausik, Parkhomenko, Alexander, McGuire, Darren, Kosiborod, Mikhail, Nguyen, Tuan Quang, Wallentin, Lars, Fox, Keith A. A., Eikelboom, John W., Tuomilehto, Jaakko, Lee, Kerry L., Al-Khalidi, Hussein R., Ellis, Stephen J., Hagström, Emil, Holmgren, Pernilla, Heldestad, Ulrika, Hallberg, Theresa, Renlund Grausne, Karin, Alm, Cristina, Michelgård Palmquist, Åsa, Svanberg, Camilla, Capell, Warren H., Nehler, Mark R., Hiatt, William R., Bonaca, Marc P., Houser, Stacey, Bachler, Susie, Jaeger, Nicole, Aunes, Maria, Brusehed, Asa, Chen, Jersey, Dahlof, Bjorn, Dolezalova, Jitka, Domzol, Maciej, Findley, Magdalena, Holmberg, Niclas, Jahreskog, Marianne, Knutsson, Mikael, Kruszewski, Jakub, Leonsson-Zachrisson, Maria, Stark, Maj, Winder, Elin, and Sinnaeve, P
- Subjects
Male ,Ticagrelor ,Cardiac & Cardiovascular Systems ,Time Factors ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Myocardial Infarction ,general clinical cardiology/adult ,Coronary Artery Disease ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Stroke/mortality ,antiplatelet therapy ,Hypoglycemic Agents/adverse effects ,Coronary artery disease ,DOUBLE-BLIND ,0302 clinical medicine ,Risk Factors ,ARTERY-DISEASE ,Medicine ,Cardiac and Cardiovascular Systems ,030212 general & internal medicine ,Myocardial infarction ,1102 Cardiorespiratory Medicine and Haematology ,Stroke ,Randomized Controlled Trials as Topic ,Aspirin ,Kardiologi ,adult ,general clinical cardiology ,60 MG ,Ticagrelor/administration & dosage ,General Medicine ,Middle Aged ,Clopidogrel ,Treatment Outcome ,CLOPIDOGREL ,diabetes mellitus ,Cardiology ,PLATELET INHIBITION ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,medicine.drug ,medicine.medical_specialty ,Trial Designs ,03 medical and health sciences ,Diabetes Mellitus, Type 2/diagnosis ,Double-Blind Method ,Internal medicine ,Humans ,Hypoglycemic Agents ,CARDIOVASCULAR EVENTS ,Aspirin/administration & dosage ,Myocardial Infarction/mortality ,Platelet Aggregation Inhibitors/administration & dosage ,Aged ,clinical trials ,Science & Technology ,business.industry ,ACUTE CORONARY SYNDROMES ,Percutaneous coronary intervention ,medicine.disease ,ischemic heart disease ,ASPIRIN ,MYOCARDIAL-INFARCTION ,Cardiovascular System & Hematology ,Clinical Trials, Phase III as Topic ,Diabetes Mellitus, Type 2 ,Cardiovascular System & Cardiology ,Coronary Artery Disease/diagnosis ,business ,THEMIS Steering Committee ,Platelet Aggregation Inhibitors - Abstract
In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double-blinded, placebo-controlled trial of ticagrelor vs placebo, on top of low dose aspirin. Patients ≥50 years with type 2 diabetes receiving anti-diabetic medications for at least 6 months with stable coronary artery disease as determined by a history of previous percutaneous coronary intervention, bypass grafting, or angiographic stenosis of ≥50% of at least one coronary artery were enrolled. Patients with known prior myocardial infarction (MI) or stroke were excluded. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. A total of 19 220 patients worldwide have been randomized and at least 1385 adjudicated primary efficacy endpoint events are expected to be available for analysis, with an expected average follow-up of 40 months (maximum 58 months). Most of the exposure is on a 60 mg twice daily dose, as the dose was lowered from 90 mg twice daily partway into the study. The results may revise the boundaries of efficacy for dual antiplatelet therapy and whether it has a role outside acute coronary syndromes, prior myocardial infarction, or percutaneous coronary intervention. ispartof: CLINICAL CARDIOLOGY vol:42 issue:5 pages:498-505 ispartof: location:United States status: published
- Published
- 2019
10. MOESM1 of Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer’s disease
- Author
-
Hansson, Oskar, Svensson, Martina, Anna-Märta Gustavsson, Andersson, Emelie, Yiyi Yang, Nägga, Katarina, Hållmarker, Ulf, James, Stefan, and Deierborg, Tomas
- Abstract
Additional file 1: Figure S1. Representative pictures of the 6E10 staining of cortex and hippocampus in sedentary and running mice respectively. Scale bar represents 100 μm. No differences were found between groups with the Mann-Whitney U-test.
- Published
- 2019
- Full Text
- View/download PDF
11. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention
- Author
-
Urban, Philip, Mehran, Roxana, Colleran, Roisin, Angiolillo, Dominick J., Byrne, Robert A., Capodanno, Davide, Cuisset, Thomas, Cutlip, Donald, Eerdmans, Pedro, Eikelboom, John, Farb, Andrew, Gibson, C. Michael, Gregson, John, Haude, Michael, James, Stefan K., Kim, Hyo-Soo, Kimura, Takeshi, Konishi, Akihide, Laschinger, John, Leon, Martin B., Magee, P.F. Adrian, Mitsutake, Yoshiaki, Mylotte, Darren, Pocock, Stuart, Price, Matthew J., Rao, Sunil V., Spitzer, Ernest, Stockbridge, Norman, Valgimigli, Marco, Varenne, Olivier, Windhoevel, Ute, Yeh, Robert W., Krucoff, Mitchell W., and Morice, Marie-Claude
- Subjects
ddc - Published
- 2019
12. Delayed Clinical Manifestation of Parkinson’s Disease Among Physically Active: Do Participants in a Long-Distance Ski Race Have a Motor Reserve?
- Author
-
Olsson, Tomas T, Svensson, Martina, Hållmarker, Ulf, James, Stefan, and Deierborg, Tomas
- Subjects
Research Report ,Adult ,Male ,Time Factors ,Cellular and Molecular Neuroscience ,Skiing ,Humans ,Cardiac and Cardiovascular Systems ,Prospective Studies ,Registries ,Exercise ,Aged ,Sweden ,Kardiologi ,exercise ,motor reserve ,Physical activity ,Parkinson Disease ,Middle Aged ,Protective Factors ,Athletes ,Parkinson’s disease ,Female ,Neurology (clinical) ,Erratum ,Follow-Up Studies - Abstract
BACKGROUND: Physical activity is associated with reduced risk of Parkinson's disease (PD). The explanations for this association are not completely elucidated. We use long-term PD-incidence data from long-distance skiers to study the relationship between exercise and PD. OBJECTIVE: We aimed to investigate if physical activity is associated with long-term lower risk of PD and if this association could be explained by physically active people being able to sustain more PD neuropathology before clinical symptoms, a motor reserve. METHODS: Using a prospective observational design, we studied whether long-distance skiers of the Swedish Vasaloppet (n = 197,685), exhibited reduced incidence of PD compared to matched individuals from the general population (n = 197,684) during 21 years of follow-up (median 10, interquartile range (IQR) 5-15 years). RESULTS: Vasaloppet skiers (median age 36.0 years [IQR 29.0-46.0], 38% women) had lower incidence of PD (HR: 0.71; 95 % CI 0.56-0.90) compared to non-skiers. When reducing risk for reverse causation by excluding PD cases within the first five years from race participation, there was still a trend for lower risk of PD (HR: 0.80; 95 % CI 0.62-1.03). Further, the PD prevalence converged between skiers and non-skiers after 15 years of follow-up, which is more consistent with a motor reserve in the physically active rather than neuroprotection. CONCLUSIONS: A physical active lifestyle is associated with reduced risk for PD. This association weakens with time and might be explained by a motor reserve among the physically active. Correction in: Journal of Parkinson's Disease, vol. 11, issue 1, page 373DOI: 10.3233/JPD-200004
- Published
- 2021
13. Sharing Data from Cardiovascular Clinical Trials — A Proposal
- Author
-
Academic Research Organization Consortium for Continuing Evaluat, Patel, Manesh R, Armstrong, Paul W, Bhatt, Deepak L, Braunwald, Eugene, Camm, A John, Fox, Keith AA, Harrington, Robert A, Hiatt, William R, James, Stefan K, Kirtane, Ajay J, Leon, Martin B, Lincoff, A Michael, Mahaffey, Kenneth W, Mauri, Laura, Mehran, Roxana, Mehta, Shamir R, Montalescot, Gilles, Nicholls, Stephen J, Perkovic, Vlado, Peterson, Eric D, Pocock, Stuart J, Roe, Matthew T, Sabatine, Marc S, Sekeres, Mikkael, Solomon, Scott D, Steg, Gabriel, Stone, Gregg W, Van de Werf, Frans, Wallentin, Lars, White, Harvey D, Gibson, Michael, Amsterdam Cardiovascular Sciences, and Vascular Medicine
- Subjects
medicine.medical_specialty ,Biomedical Research ,MEDLINE ,Alternative medicine ,Information Dissemination ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,General & Internal Medicine ,Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies--Cardiovascular (ACCESS CV) ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Clinical Trials as Topic ,business.industry ,Medicine (all) ,Periodicals as Topic ,Cardiovascular Diseases ,Editorial Policies ,11 Medical And Health Sciences ,General Medicine ,Clinical trial ,business - Published
- 2016
14. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK
- Author
-
Chung, Sheng-Chia, Gedeborg, Rolf, Nicholas, Owen, James, Stefan, Jeppsson, Anders, Wolfe, Charles, Heuschmann, Peter, Wallentin, Lars, Deanfield, John, Timmis, Adam, Jernberg, Tomas, and Hemingway, Harry
- Subjects
Medicine(all) ,Medicin och hälsovetenskap ,REPERFUSION THERAPY ,MORTALITY-RATES ,FOCUSED UPDATE ,PERCUTANEOUS CORONARY INTERVENTION ,ST-ELEVATION ,Medical and Health Sciences ,EUROPEAN-SOCIETY ,ACC/AHA GUIDELINES ,PRACTICE GUIDELINES ,ddc:610 ,ASSOCIATION TASK-FORCE ,CARDIOLOGY - Abstract
SummaryBackgroundInternational research for acute myocardial infarction lacks comparisons of whole health systems. We assessed time trends for care and outcomes in Sweden and the UK.MethodsWe used data from national registries on consecutive patients registered between 2004 and 2010 in all hospitals providing care for acute coronary syndrome in Sweden and the UK. The primary outcome was all-cause mortality 30 days after admission. We compared effectiveness of treatment by indirect casemix standardisation. This study is registered with ClinicalTrials.gov, number NCT01359033.FindingsWe assessed data for 119 786 patients in Sweden and 391 077 in the UK. 30-day mortality was 7·6% (95% CI 7·4–7·7) in Sweden and 10·5% (10·4–10·6) in the UK. Mortality was higher in the UK in clinically relevant subgroups defined by troponin concentration, ST-segment elevation, age, sex, heart rate, systolic blood pressure, diabetes mellitus status, and smoking status. In Sweden, compared with the UK, there was earlier and more extensive uptake of primary percutaneous coronary intervention (59% vs 22%) and more frequent use of β blockers at discharge (89% vs 78%). After casemix standardisation the 30-day mortality ratio for UK versus Sweden was 1·37 (95% CI 1·30–1·45), which corresponds to 11 263 (95% CI 9620–12 827) excess deaths, but did decline over time (from 1·47, 95% CI 1·38–1·58 in 2004 to 1·20, 1·12–1·29 in 2010; p=0·01).InterpretationWe found clinically important differences between countries in acute myocardial infarction care and outcomes. International comparisons research might help to improve health systems and prevent deaths.FundingSeventh Framework Programme for Research, National Institute for Health Research, Wellcome Trust (UK), Swedish Association of Local Authorities and Regions, Swedish Heart-Lung Foundation.
- Published
- 2014
- Full Text
- View/download PDF
15. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
- Author
-
Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J, Borger, Michael A, Brotons, Carlos, Chew, Derek P, Gencer, Baris, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F, Windecker, Stephan, Patrono, Marco, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thomas, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathios, James, Stefan, Lewis, Basil S, Lip, Gregory y H, Piepoli, Massimo F, Richter, Dimitrios, Rosemann, Thomas, Sechtem, Udo, Steg, Ph Gabriel, Vrints, Christian, Luis Zamorano, Jose, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J, Borger, Michael A, Brotons, Carlo, Chew, Derek P, Gencer, Bari, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F, Windecker, Stephan, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thoma, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathio, James, Stefan, Lewis, Basil S, Lip, Gregory Y H, Piepoli, Massimo F, Richter, Dimitrio, Rosemann, Thoma, Sechtem, Udo, Steg, Ph Gabriel, Vrints, Christian, Luis Zamorano, Jose, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, and Cardiology
- Subjects
High-sensitivity troponin ,Ticagrelor ,Chest pain unit ,medicine.medical_treatment ,Atherothrombosis ,Myocardial ischaemia ,Recommendations ,MESH: Risk Assessment ,Early invasive strategy ,Electrocardiography ,Acute cardiac care ,Acute coronary syndromes ,Angioplasty ,Anticoagulation ,Apixaban ,Aspirin ,Beta-blockers ,Bivalirudin ,Bypass surgery ,Cangrelor ,Clopidogrel ,Dabigatran ,Diabetes ,Enoxaparin ,European society of cardiology ,Fondaparinux ,Glycoprotein IIb/IIIa inhibitors ,Guidelines ,Heparin ,Nitrates ,Non-ST-elevation myocardial infarction ,Platelet inhibition ,Prasugrel ,Revascularization ,Rhythm monitoring ,Rivaroxaban ,Statin ,Stent ,Unstable angina ,Vorapaxar ,Cardiology and Cardiovascular Medicine ,ST segment ,Myocardial infarction ,610 Medicine & health ,ComputingMilieux_MISCELLANEOUS ,MESH: Platelet Glycoprotein GPIIb-IIIa Complex ,Platelet aggregation inhibitor ,MESH: Percutaneous Coronary Intervention ,MESH: Hemorrhage ,medicine.medical_specialty ,Acute coronary syndrome ,Cardiotonic Agents ,MESH: Algorithms ,Hemorrhage ,Platelet Glycoprotein GPIIb-IIIa Complex ,MESH: Anticoagulants ,Risk Assessment ,Percutaneous Coronary Intervention ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Humans ,Acute Coronary Syndrome ,Physical Examination ,Management of acute coronary syndrome ,MESH: Humans ,MESH: Cardiotonic Agents ,Recommendation ,medicine.disease ,MESH: Acute Coronary Syndrome ,Long-Term Care ,MESH: Coronary Angiography ,MESH: Non-ST Elevated Myocardial Infarction ,Purinergic P2Y Receptor Antagonists ,Human medicine ,Biomarkers ,Guideline ,Diabete ,Nitrate ,Coronary Angiography ,MESH: Angina Pectoris ,MESH: Long-Term Care ,Non-ST Elevated Myocardial Infarction ,reproductive and urinary physiology ,Atherothrombosi ,MESH: Platelet Aggregation Inhibitors ,embryonic structures ,Cardiology ,MESH: Purinergic P2Y Receptor Antagonists ,biological phenomena, cell phenomena, and immunity ,Algorithms ,medicine.drug ,Settore BIO/14 - FARMACOLOGIA ,Glycoprotein IIb/IIIa inhibitor ,European Society of Cardiology ,Angina Pectoris ,Diagnosis, Differential ,MESH: Physical Examination ,MESH: Diagnosis, Differential ,Internal medicine ,medicine ,Beta-blocker ,urogenital system ,business.industry ,Percutaneous coronary intervention ,Anticoagulants ,MESH: Electrocardiography ,MESH: Biomarkers ,business ,Platelet Aggregation Inhibitors - Abstract
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
- Published
- 2015
16. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years
- Author
-
Serruys, Patrick W., Farooq, Vasim, Vranckx, Pascal, Girasis, Chrysafios, Brugaletta, Salvatore, Garcia-Garcia, Hector M., Holmes, David R., Kappetein, Arie-Pieter, Mack, Michael J., Feldman, Ted, Morice, Marie-Claude, Ståhle, Elisabeth, James, Stefan, Colombo, Antonio, Pereda, Peggy, Huang, Jian, Morel, Marie-Angèle, Van Es, Gerrit-Anne, Dawkins, Keith D., Mohr, Friedrich W., Steyerberg, Ewout W., Cardiology, Cardiothoracic Surgery, and Public Health
- Subjects
Male ,Time Factors ,Heart Diseases ,Coronary Artery Disease ,Kaplan-Meier Estimate ,Risk Assessment ,Severity of Illness Index ,Decision Support Techniques ,SYNTAX Score ,Risk Factors ,Humans ,cardiovascular diseases ,Prospective Studies ,Registries ,Angioplasty, Balloon, Coronary ,Coronary Artery Bypass ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,Patient Selection ,Drug-Eluting Stents ,Middle Aged ,left main disease ,Cerebrovascular Disorders ,surgical procedures, operative ,Logistic Models ,Treatment Outcome ,Global Risk ,Female ,3-vessel disease ,Algorithms - Abstract
ObjectivesThe aim of this study was to assess the additional value of the Global Risk—a combination of the SYNTAX Score (SXscore) and additive EuroSCORE—in the identification of a low-risk population, who could safely and efficaciously be treated with coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI).BackgroundPCI is increasingly acceptable in appropriately selected patients with left main stem or 3-vessel coronary artery disease.MethodsWithin the SYNTAX Trial (Synergy between PCI with TAXUS and Cardiac Surgery Trial), all-cause death and major adverse cardiac and cerebrovascular events (MACCE) were analyzed at 36 months in low (GRCLOW) to high Global Risk groups, with Kaplan-Meier, log-rank, and Cox regression analyses.ResultsWithin the randomized left main stem population (n = 701), comparisons between GRCLOW groups demonstrated a significantly lower mortality with PCI compared with CABG (CABG: 7.5%, PCI: 1.2%, hazard ratio [HR]: 0.16, 95% confidence interval [CI]: 0.03 to 0.70, p = 0.0054) and a trend toward reduced MACCE (CABG: 23.1%, PCI: 15.8%, HR: 0.64, 95% CI: 0.39 to 1.07, p = 0.088). Similar analyses within the randomized 3-vessel disease population (n = 1,088) demonstrated no statistically significant differences in mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95% CI: 0.57 to 2.30, p = 0.71) or MACCE (CABG: 19.0%, PCI: 24.7%, HR: 1.35, 95% CI: 0.95 to 1.92, p = 0.10). Risk-model performance and reclassification analyses demonstrated that the EuroSCORE—with the added incremental benefit of the SXscore to form the Global Risk—enhanced the risk stratification of all PCI patients.ConclusionsIn comparison with the SXscore, the Global Risk, with a simple treatment algorithm, substantially enhances the identification of low-risk patients who could safely and efficaciously be treated with CABG or PCI.
- Published
- 2012
17. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
- Author
-
Thompson, Alexander, Gao, Pei, Orfei, Lia, Watson, Sarah, Di Angelantonio, Emanuele, Kaptoge, Stephen, Ballantyne, Christie, Cannon, Christopher P., Criqui, Michael, Cushman, Mary, Hofman, Albert, Packard, Chris, Thompson, Simon G., Collins, Rory, Danesh, John, Willeit, Johann, Kiechl, Stefan, Wiedemann, Christian, Psaty, Bruce, Furberg, Curt, Khaw, Kay-Tee, Sandhu, Manjinder, Benjamin, Emelia J., Vasan, Ramachandran S., Schnabel, Renate B., Oldgren, Jonas, Rossi, Gian Paolo, Cesari, Maurizio, Lenzini, Livia, Zanchetta, Mario, James, Stefan K., Rimm, Eric, Hatoum, Ida, Anderson, Jeffrey L., May, Heidi T., Home, Benjamin D., Carlquist, John F., Muhlestein, Joseph B., Koenig, Wolfgang, Hermann Brenner, Rothenbacher, Dietrich, Maerz, Winfried, Boehm, Bernhard, Winkelmann, Bernhard R., Winkler, Karl, Berglund, Goran, Persson, Margaretha, Roger, Veronique, Gerber, Yariv, Berger, Peter B., Brilakis, Emmanouil S., Mcconnell, Joseph P., Meisinger, Christa, Sacco, Ralph, Elkind, Mitchell, Talmud, Philippa J., O Donoghue, Michelle, Sabatine, Marc S., Morrow, David A., Caslake, Muriel, Braunwald, Eugene, Barrett-Connor, Elizabeth, Daniels, Lori B., Laughlin, Gail A., Kardys, Isabella, Witteman, Jacqueline C. M., Corsetti, James P., Rainwater, David L., Moss, Arthur J., Wassertheil-Smoller, Sylvia, Ridker, Paul, Nelson, Jeanenne J., Zariffa, Nevine, Zalewski, Andrew, and Walker, Mat
- Subjects
Male ,medicine.medical_specialty ,Heart disease ,Systole ,Blood Pressure ,Coronary Disease ,030204 cardiovascular system & hematology ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Darapladib ,Internal medicine ,medicine ,Fast track — Articles ,Humans ,Myocardial infarction ,Prospective Studies ,Risk factor ,Particle Size ,030304 developmental biology ,Apolipoproteins B ,0303 health sciences ,Framingham Risk Score ,business.industry ,Vascular disease ,Lipoprotein-associated phospholipase A2 ,General Medicine ,Middle Aged ,medicine.disease ,Lipids ,3. Good health ,Lipoproteins, LDL ,Stroke ,Blood pressure ,1-Alkyl-2-acetylglycerophosphocholine Esterase ,Cardiology ,Linear Models ,lipids (amino acids, peptides, and proteins) ,Female ,business ,Biomarkers - Abstract
Background Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), an inflammatory enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials of vascular disease prevention. We investigated associations of circulating Lp-PLA(2) mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances. Methods With use of individual records from 79 036 participants in 32 prospective studies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we did a meta-analysis of within-study regressions to calculate risk ratios (RRs) per 1 SD higher value of Lp-PLA(2) or other risk factor. The primary outcome was coronary heart disease. Findings Lp-PLA(2) activity and mass were associated with each other (r=0.51, 95% CI 0.47-0.56) and proatherogenic lipids. We noted roughly log-linear associations of Lp-PLA(2) activity and mass with risk of coronary heart disease and vascular death. RRs, adjusted for conventional risk factors, were: 1.10 (95% CI 1.05-1.16) with Lp-PLA(2) activity and 1.11 (1.07-1.16) with Lp-PLA(2) mass for coronary heart disease; 1.08 (0.97-1.20) and 1.14 (1.02-1.27) for ischaemic stroke; 1.16 (1.09-1.24) and 1.13 (1.05-1.22) for vascular mortality; and 1.10 (1.04-1.17) and 1.10 (1.03-1.18) for non-vascular mortality, respectively. RRs with Lp-PLA(2) did not differ significantly in people with and without initial stable vascular disease, apart from for vascular death with Lp-PLA(2) mass. Adjusted RRs for coronary heart disease were 1.10 (1.02-1.18) with non-HDL cholesterol and 1.10 (1.00-1.21) with systolic blood pressure. Interpretation Lp-PLA(2) activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure in this population. Associations of Lp-PLA(2) mass and activity are not exclusive to vascular outcomes, and the vascular associations depend at least partly on lipids. Funding UK Medical Research Council, GlaxoSmithKline, and British Heart Foundation.
- Published
- 2010
18. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
- Author
-
European Association, for Percutaneous Cardiovascular Interventions, Wijns, William, Kolh, Philippe, Danchin, Nicolas, Di Mario, Carlo, Falk, Volkmar, Folliguet, Thierry, Garg, Scot, Huber, Kurt, James, Stefan, Knuuti, Juhani, Lopez-Sendon, Jose, Marco, Jean, Menicanti, Lorenzo, Ostojic, Miodrag, Piepoli, Massimo F, Pirlet, Charles, Pomar, Jose L, Reifart, Nicolaus, Ribichini, Flavio L, Schalij, Martin J, Sergeant, Paul, Serruys, Patrick W, Silber, Sigmund, Sousa Uva, Miguel, Taggart, David, ESC Committee, for Practice Guidelines, Vahanian, Alec, Auricchio, Angelo, Bax, Jeroen, Ceconi, Claudio, Dean, Veronica, Filippatos, Gerasimos, Funck-Brentano, Christian, Hobbs, Richard, Kearney, Peter, McDonagh, Theresa, Popescu, Bogdan A, Reiner, Zeljko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Vardas Panos, E, Widimsky, Petr, EACTS Clinical Guidelines, Committee, Alfieri, Ottavio, Dunning, Joel, Elia, Stefano, Kappetein, Pieter, Lockowandt, Ulf, Sarris, George, Vouhe, Pascal, von Segesser, Ludwig, Agewall, Stefan, Aladashvili, Alexander, Alexopoulos, Dimitrios, Antunes, Manuel J, Atalar, Enver, Brutel de la Riviere, Aart, Doganov, Alexander, Eha, Jaan, Fajadet, Jean, Ferreira, Rafael, Garot, Jerome, Halcox, Julian, Hasin, Yonathan, Janssens, Stefan, Kervinen, Kari, Laufer, Gunther, Legrand, Victor, Nashef Samer, A M, Neumann, Franz-Josef, Niemela, Kari, Nihoyannopoulos, Petros, Noc, Marko, Piek, Jan J, Pirk, Jan, Rozenman, Yoseph, Sabate, Manel, Starc, Radovan, Thielmann, Matthias, Wheatley, David J, Windecker, Stephan, and Zembala, Marian
- Subjects
myocardial ,revascularization ,medicine.medical_specialty ,business.industry ,Judgement ,Medizin ,MEDLINE ,Conflict of interest ,EuroSCORE ,Evidence-based medicine ,medicine.disease ,Coronary artery bypass surgery ,Cardiothoracic surgery ,Internal medicine ,medicine ,Cardiology ,Medical emergency ,Cardiology and Cardiovascular Medicine ,Risk assessment ,business - Abstract
Guidelines and Expert Consensus Documents summarize and evaluate all available evidence with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome and the risk–benefit ratio of diagnostic or therapeutic means. Guidelines are no substitutes for textbooks and their legal implications have been discussed previously. Guidelines and recommendations should help physicians to make decisions in their daily practice. However, the ultimate judgement regarding the care of an individual patient must be made by his/her responsible physician(s). The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (http://www.escardio.org/knowledge/guidelines/rules). Members of this Task Force were selected by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) to represent all physicians involved with the medical and surgical care of patients with coronary artery disease (CAD). A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk–benefit ratio. Estimates of expected health outcomes for society are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in Tables 1 and 2 . View this table: Table 1 Classes of recommendations View this table: Table 2 Levels of evidence The members of the Task Force have provided disclosure statements of all relationships that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at European Heart House, headquarters of the ESC. Any changes in conflict of interest that arose during the writing period were notified to the ESC. The Task Force report received its entire financial support from the ESC and EACTS, without any involvement of the pharmaceutical, device, or surgical industry. ESC …
- Published
- 2010
- Full Text
- View/download PDF
19. ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
- Author
-
Daemen, Joost, Simoons, Maarten L, Wijns, William, Bagust, Adrian, Bos, Gert, Bowen, James M, Braunwald, Eugene, Camenzind, Edoardo, Chevalier, Bernard, Dimario, Carlo, Fajadet, Jean, Gitt, Anselm, Guagliumi, Giulio, Hillege, Hans L, James, Stefan, Jüni, Peter, Kastrati, Adnan, Kloth, Sabine, Kristensen, Steen D, Krucoff, Mitchell, Legrand, Victor, Pfisterer, Matthias, Rothman, Martin, Serruys, Patrick W, Silber, Sigmund, Steg, Philippe G, Tariah, Ibrahim, Wallentin, Lars, Windecker, Stephan W, Aimonetti, A, Allocco, D, Baczynska, A, Bagust, A, Berenger, M, Bos, G, Boam, A, Bowen, J M, Braunwald, E, Calle, J P, Camenzind, E, Campo, G, Carlier, S, Chevalier, B, Daemen, J, de Schepper, J, Di Bisceglie, G, Dimario, C, Dobbels, H, Fajadet, J, Farb, A, Ghislain, J C, Gitt, A, Guagliumi, G, Hellbardt, S, Hillege, H L, Ten Hoedt, R, Isaia, C, James, S, de Jong, P, Jüni, P, Kastrati, A, Klasen, E, Kloth, S, Kristensen, S D, Krucoff, M, Legrand, V, Lekehal, M, Lenarz, L, Ni Mhullain, F, Nagai, H, Patteet, A, Paunovic, D, Pfisterer, M, Potgieter, A, Purdy, I, Raveau-Landon, C, Rothman, M, Serruys, P W, Silber, S, Simoons, M L, Steg, P G, Tariah, I, Ternstrom, S, Van Wuytswinkel, J, Waliszewski, M, Wallentin, L, Wijns, W, and Windecker, S W
- Abstract
Udgivelsesdato: 2009-Jan
- Published
- 2009
- Full Text
- View/download PDF
20. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers
- Author
-
Westerhout, Cynthia M., Fu, Yuling, Lauer, Michael S., James, Stefan, Armstrong, Paul W., Al-Hattab, Eyad, Califf, Robert M., Simoons, Maarten L., Wallentin, Lars, Boersma, Eric, and Cardiology
- Abstract
ObjectivesThe purpose of this study was to develop 30-day and 1-year risk stratification models for non–ST-segment elevation acute coronary syndrome (NSTE-ACS) patients that incorporate quantitative ST-segment depression and novel biomarkers.BackgroundSeveral novel biomarkers have changed the risk profile of ACS; thus, the reassessment of traditional indicators such as ST-segment depression in this new context is warranted.MethodsMultivariable logistic regression was used to identify significant predictors of 30-day death and death/myocardial infarction (MI) and 1-year mortality in 7,800 NSTE-ACS patients enrolled in the GUSTO-IV (Global Utilization of Strategies to Open Occluded Arteries-IV ACS) trial between 1998 and 2000.ResultsAmong all other predictors, the degree of ST-segment depression had the highest prognostic value for 30-day death, 30-day death/MI, and 1-year death. Troponin T (TnT), creatinine clearance, N-terminal pro-brain natriuretic peptide (NT-proBNP), heart rate, and age were also highly influential on adverse outcomes. Unlike TnT and NT-proBNP, C-reactive protein was only predictive of long-term death. In contrast to mortality, the contribution of TnT to predicting 30-day death/MI increased, whereas NT-proBNP’s role was attenuated. The discriminatory power was excellent (c-index [adjusted for over-optimism]: 0.82 [30-day death]; 0.72 [30-day death/MI]; 0.81 [1-year]).ConclusionsIn this large contemporary study of NSTE-ACS patients, novel insights into risk stratification were observed—in particular, the utility of quantitative ST-segment depression and multiple biomarkers. Collection of these indicators in future NSTE-ACS populations is recommended to evaluate generalizability and clinical application of these findings.
- Published
- 2006
21. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy
- Author
-
James, Stefan K, Armstrong, Paul, Barnathan, Elliott, Califf, Robert, Lindahl, Bertil, Siegbahn, Agneta, Simoons, Maarten L, Topol, Eric J, Venge, Per, Wallentin, Lars, and Cardiology
- Subjects
musculoskeletal system - Abstract
ObjectivesWe sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS).BackgroundBoth CRP and TnT predict risk of future coronary events in patients with ACS. However, the relationships between the levels of the markers and the individual end points are still unclear.MethodsBaseline levels of CRP and TnT were determined in 7,108 patients with ACS not undergoing early revascularization in the Global Use of Strategies To Open occluded arteries trial IV (GUSTO-IV) trial and related to outcome at 30 days.ResultsQuartiles of TnT related to 30-day mortality, which was 1.1%, 3.7%, 3.7%, and 7.4% (p < 0.001) and to the rate of MI: 2.5%, 6.7%, 7.2%, and 5.6% (p < 0.001). Quartiles of CRP also related to 30-day mortality, which was 2.0%, 3.3%, 3.9%, and 6.3% (p < 0.001), whereas there was no relationship to the 30-day rate of MI: 5.6%, 4.7%, 5.2%, and 5.9% (p = 0.48). On multivariable analysis, both TnT and CRP were independent predictors of mortality, but only TnT was a predictor of MI. The combination of CRP and TnT provides an even better risk stratification of mortality, with 0.3% and 9.1% death rates, respectively, when both markers are in the bottom versus top quartiles.ConclusionsIn ACS, baseline levels of TnT and CRP are independently related to 30-day mortality. Any detectable elevation of TnT, but not of CRP, is also associated with an increased risk of subsequent MI. Regarding mortality, the combination of both markers provides a better risk stratification than either one alone.
- Published
- 2003
22. Guidelines for myocardial revascularization
- Author
-
Wijns, William, Kolh, Philippe, Danchin, Nicolas, Di Mario, Carlo, Falk, Volkmar, Folliguet, Thierry, Garg, Scot, Huber, Kurt, James, Stefan, Knuuti, Juhani, Lopez-Sendon, Jose, Marco, Jean, Menicanti, Lorenzo, Ostojic, Miodrag, Massimo Piepoli, Pirlet, Charles, Pomar, Jose L., Reifart, Nicolaus, Ribichini, Flavio L., Schalij, Martin J., Sergeant, Paul, Serruys, Patrick W., Silber, Sigmund, Uva, Miguel Sousa, and Taggart, David
23. 2013 ESC guidelines on the management of stable coronary artery disease
- Author
-
Montalescot, Gilles, Sechtem, Udo, Achenbach, Stephan, Andreotti, Felicita, Arden, Chris, Budaj, Andrzej, Bugiardini, Raffaele, Crea, Filippo, Cuisset, Thomas, Di Mario, Carlo, Ferreira, J. Rafael, Gersh, Bernard J., Gitt, Anselm K., Hulot, Jean-Sebastien, Marx, Nikolaus, Opie, Lionel H., Pfisterer, Matthias, Prescott, Eva, Ruschitzka, Frank, Sabate, Manel, Senior, Roxy, Taggart, David Paul, Wall, Ernst E., Vrints, Christiaan J. M., Zamorano, Jose Luis, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Hector, Dean, Veronica, Deaton, Christi, Erol, Cetin, Fagard, Robert, Ferrari, Roberto, Hasdai, David, Hoes, Arno W., Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, Lancellotti, Patrizio, Linhart, Ales, Nihoyannopoulos, Petros, Piepoli, Massimo F., Ponikowski, Piotr, Sirnes, Per Anton, Tamargo, Juan Luis, Tendera, Michal, Torbicki, Adam, Wijns, William, Windecker, Stephan, Valgimigli, Marco, Claeys, Marc J., Donner-Banzhoff, Norbert, Frank, Herbert, Funck-Brentano, Christian, Gaemperli, Oliver, Gonzalez-Juanatey, Jose R., Hamilos, Michalis, Husted, Steen, James, Stefan K., Kervinen, Kari, Kristensen, Steen Dalby, Maggioni, Aldo Pietro, Pries, Axel R., Ryden, Lars, Simoons, Maarten L., Steg, Ph Gabriel, Timmis, Adam, and Aylin YILDIRIR
24. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
- Author
-
Thompson, Alexander, Pei Gao, Orfei, Lia, Watson, Sarah, Di Angelantonio, Emanuele, Kaptoge, Stephen, Ballantyne, Christie, Cannon, Christopher P., Criqui, Michael, Cushman, Mary, Hofman, Albert, Packard, Chris, Thompson, Simon G., Collins, Rory, Danesh, John, Willeit, Johann, Kiechl, Stefan, Wiedemann, Christian, Psaty, Bruce, Furberg, Curt, Khaw, Kay-Tee, Sandhu, Manjinder, Benjamin, Emelia J., Vasan, Ramachandran S., Schnabel, Renate B., Oldgren, Jonas, Rossi, Gian Paolo, Cesari, Maurizio, Lenzini, Livia, Zanchetta, Mario, James, Stefan K., Rimm, Eric, Hatoum, Ida, Anderson, Jeffrey L., May, Heidi T., Home, Benjamin D., Carlquist, John F., Muhlestein, Joseph B., Koenig, Wolfgang, Brenner, Herrnann, Rothenbacher, Dietrich, Maerz, Winfried, Boehm, Bernhard, Winkelmann, Bernhard R., Winkler, Karl, Berglund, Goran, Persson, Margaretha, Roger, Veronique, Gerber, Yariv, Berger, Peter B., Brilakis, Emmanouil S., Mcconnell, Joseph P., Meisinger, Christa, Sacco, Ralph, Elkind, Mitchell, Talmud, Philippa J., O Donoghue, Michelle, Sabatine, Marc S., Morrow, David A., Caslake, Muriel, Braunwald, Eugene, Barrett-Connor, Elizabeth, Daniels, Lori B., Laughlin, Gail A., Kardys, Isabella, Witteman, Jacqueline C. M., Corsetti, James P., Rainwater, David L., Moss, Arthur J., Wassertheil-Smoller, Sylvia, Ridker, Paul, Nelson, Jeanenne J., Zariffa, Nevine, Zalewski, Andrew, Walker, Mat, and Lp-PLA2 Studies Collaboration
25. Sex-Related Differences in Thrombus Burden in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention
- Author
-
Maria Virginia Manzi, Sergio Buccheri, Sanjit S. Jolly, Felix Zijlstra, Ole Frøbert, Bo Lagerqvist, Karim D. Mahmoud, Vladimír Džavík, Emanuele Barbato, Giovanna Sarno, Stefan James, Manzi, Maria Virginia, Buccheri, Sergio, Jolly, Sanjit S, Zijlstra, Felix, Frøbert, Ole, Lagerqvist, Bo, Mahmoud, Karim D, Džavík, Vladimír, Barbato, Emanuele, Sarno, Giovanna, James, Stefan, and Cardiology
- Subjects
Male ,TAPAS ,Kardiologi ,TASTE ,Coronary Thrombosis ,TOTAL ,ST-segment elevation myocardial infarction ,Percutaneous Coronary Intervention ,Treatment Outcome ,TIMI thrombus burden ,Humans ,ST Elevation Myocardial Infarction ,Female ,Cardiac and Cardiovascular Systems ,women ,Neoplasm Recurrence, Local ,Cardiology and Cardiovascular Medicine ,Thrombectomy - Abstract
Background: Women have a worse prognosis after ST-segment elevation myocardial infarction (STEMI) than men. The prognostic role of thrombus burden (TB) in influencing the sex-related differences in clinical outcomes after STEMI has not been clearly investigated. Objectives: The aim of this study was to assess the sex-related differences in TB and its clinical implications in patients with STEMI. Methods: Individual patient data from the 3 major randomized clinical trials of manual thrombus aspiration were analyzed, encompassing a total of 19,047 patients with STEMI, of whom 13,885 (76.1%) were men and 4,371 (23.9%) were women. The primary outcome of interest was 1-year cardiovascular (CV) death. The secondary outcomes of interest were recurrent myocardial infarction, heart failure, all-cause mortality, stroke, stent thrombosis (ST), and target vessel revascularization at 1 year. Results: Patients with high TB (HTB) had worse 1-year outcomes compared with those presenting with low TB (adjusted HR for CV death: 1.52; 95% CI: 1.10-2.12; P = 0.01). In unadjusted analyses, female sex was associated with an increased risk for 1-year CV death regardless of TB. After adjustment, the risk for 1-year CV death was higher only in women with HTB (HR: 1.23; 95% CI: 1.18-1.28; P < 0.001), who also had an increased risk for all-cause death and ST than men. Conclusions: In patients with STEMI, angiographic evidence of HTB negatively affected prognosis. Among patients with HTB, women had an excess risk for ST, CV, and all-cause mortality than men. Further investigations are warranted to better understand the pathophysiological mechanisms leading to excess mortality in women with STEMI and HTB.
- Published
- 2022
26. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease. Two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC) and European Association of Preventive Cardiology (EAPC)
- Author
-
Eliano Pio Navarese, Antonio Landi, Angelo Oliva, Raffaele Piccolo, Victor Aboyans, Dominick Angiolillo, Dan Atar, Davide Capodanno, Keith A A Fox, Sigrun Halvorsen, Stefan James, Peter Jüni, Vijay Kunadian, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Josef Niebauer, Susanna Price, Robert F Storey, Heinz Völler, Pascal Vranckx, Stephan Windecker, Marco Valgimigli, Oliva, Angelo/0000-0003-0561-7563, Juni, Peter/0000-0002-5985-0670, Storey, Robert/0000-0002-6677-6229, Leonardi, Sergio/0000-0002-4800-6132, Navarese, Eliano Pio, Landi, Antonio, Oliva, Angelo, Piccolo, Raffaele, Aboyans, Victor, Angiolillo, Dominick, Atar, Dan, Capodanno, Davide, Fox, Keith A. A., Halvorsen, Sigrun, James, Stefan, Juni, Peter, Kunadian, Vijay, Leonardi, Sergio, Mehran, Roxana, Montalescot, Gilles, Niebauer, Josef, Price, Susanna, Storey, Robert F., Voller, Heinz, VRANCKX, Pascal, Windecker, Stephan, and Valgimigli, Marco
- Subjects
Antithrombotics ,Pharmacology (medical) ,Cardiology and Cardiovascular Medicine ,Network meta-analysis ,610 Medicine & health ,Coronary artery disease - Abstract
Aims To appraise all available antithrombotic treatments within or after 12 months following coronary revascularization and/or acute coronary syndrome in two network meta-analyses. Methods and results Forty-three (N = 189 261 patients) trials within 12 months and 19 (N = 139 086 patients) trials beyond 12 months were included for efficacy/safety endpoints appraisal. Within 12 months, ticagrelor 90 mg bis in die (b.i.d.) [hazard ratio (HR), 0.66; 95% confidence interval (CI), 0.49–0.88], aspirin and ticagrelor 90 mg (HR, 0.85; 95% CI, 0.76–0.95), or aspirin, clopidogrel and rivaroxaban 2.5 mg b.i.d. (HR, 0.66; 95% CI, 0.51–0.86) were the only treatments associated with lower cardiovascular mortality, compared with aspirin and clopidogrel, without or with greater bleeding risk for the first and the other treatment options, respectively. Beyond 12 months, no strategy lowered mortality; compared with aspirin; the greatest reductions of myocardial infarction (MI) were found with aspirin and clopidogrel (HR, 0.68; 95% CI, 0.55–0.85) or P2Y12 inhibitor monotherapy (HR, 0.76; 95% CI: 0.61–0.95), especially ticagrelor 90 mg (HR, 0.54; 95% CI, 0.32–0.92), and of stroke with VKA (HR, 0.56; 95% CI, 0.44–0.76) or aspirin and rivaroxaban 2.5 mg (HR, 0.58; 95% CI, 0.44–0.76). All treatments increased bleeding except P2Y12 monotherapy, compared with aspirin. Conclusion Within 12 months, ticagrelor 90 mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel. Beyond 12 months, P2Y12 monotherapy, especially ticagrelor 90 mg, was associated with lower MI without bleeding trade-off; aspirin and rivaroxaban 2.5 mg most effectively reduced stroke, with a more acceptable bleeding risk than VKA, compared with aspirin. Registration URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifiers: CRD42021243985 and CRD42021252398.
- Published
- 2023
- Full Text
- View/download PDF
27. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
- Author
-
Ewout W. Steyerberg, Dik Heg, Francesco Costa, Myeong Ki Hong, Tullio Palmerini, Thomas Zanchin, Stefan James, Thomas Pilgrim, Antonio Colombo, Philippe Gabriel Steg, David van Klaveren, Deepak L. Bhatt, Fausto Feres, Marco Valgimigli, Gregg W. Stone, Stephan Windecker, Hyo-Soo Kim, Lars Wallentin, Lorenz Räber, Cardiology, Public Health, Costa, Francesco, Van Klaveren, David, James, Stefan, Heg, Dik, Rã¤ber, Lorenz, Feres, Fausto, Pilgrim, Thoma, Hong, Myeong ki, Kim, Hyo soo, Colombo, Antonio, Steg, Philippe Gabriel, Zanchin, Thoma, Palmerini, Tullio, Wallentin, Lar, Bhatt, Deepak L, Stone, Gregg W, Windecker, Stephan, Steyerberg, Ewout W, and Valgimigli, Marco
- Subjects
medicine.medical_specialty ,Ticlopidine ,medicine.medical_treatment ,Myocardial Infarction ,Hemorrhage ,Context (language use) ,Coronary Artery Disease ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Lower risk ,Risk Assessment ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Multicenter Studies as Topic ,030212 general & internal medicine ,Aged ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,Aspirin ,Framingham Risk Score ,business.industry ,Medicine (all) ,Percutaneous coronary intervention ,General Medicine ,Middle Aged ,Clopidogrel ,Surgery ,Clinical trial ,Treatment Outcome ,Purinergic P2Y Receptor Antagonists ,Drug Therapy, Combination ,Stents ,business ,Platelet Aggregation Inhibitors ,TIMI ,medicine.drug - Abstract
Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases bleeding. Guidelines support weighting bleeding risk before the selection of treatment duration, but no standardised tool exists for this purpose. Methods A total of 14â963 patients treated with DAPT after coronary stentingâlargely consisting of aspirin and clopidogrel and without indication to oral anticoagulationâwere pooled at a single-patient level from eight multicentre randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we identified predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed within patients randomised to different DAPT durations (n=10â081) to identify the effect on bleeding and ischaemia of a long (12â24 months) or short (3â6 months) treatment in relation to baseline bleeding risk. Findings The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61â0·85) in the derivation cohort, and 0·70 (0·65â0·74) in the PLATO trial validation cohort and 0·66 (0·61â0·71) in the BernPCI registry validation cohort. A longer DAPT duration significantly increased bleeding in patients at high risk (score â¥25), but not in those with lower risk profiles (pinteraction=0·007), and exerted a significant ischaemic benefit only in this latter group. Interpretation The PRECISE-DAPT score is a simple five-item risk score, which provides a standardised tool for the prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, this tool can support clinical decision making for treatment duration. Funding None.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.